BACKGROUND AND PURPOSE: The purpose of the present study was to determine whether a stimulator of soluble guanylyl cyclase, BAY 41-2272, inhibits platelet aggregation and to clarify its interaction with nitric oxide (NO). EXPERIMENTAL APPROACH: Blood was collected from anaesthetized Wistar Kyoto rats. The aggregation of washed platelets was measured and the production of cAMP and cGMP was determined. KEY RESULTS: In adenosine 5'-diphosphate (ADP)-induced platelet aggregation, the anti-aggregating effects of BAY 41-2272, nitroglycerin, sodium nitroprusside and DEA-NONOate were associated with increased levels of cGMP while that of beraprost, a prostacyclin analogue, was correlated with an increase in cAMP. 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) prevented the effects of BAY 41-2272 and that of nitroglycerin and sodium nitroprusside, but only inhibited the increase in cGMP produced by of DEA-NONOate. Hydroxocobalamin, an NO scavenger, inhibited the effects of the three NO donors and BAY 41-2272 but did not affect those of beraprost. ADP-induced aggregation and the effects of BAY 41-2272 were not affected by L-nitroarginine. A positive interaction was observed between BAY 41-2272 and the three NO donors. BAY 41-2272 potentiated also the anti-aggregating effects of beraprost, and again this potentiation was inhibited by hydroxocobalamin. CONCLUSIONS AND IMPLICATIONS: Inhibition of platelet aggregation by BAY 41-2272 requires the reduced form of soluble guanylyl cyclase and the presence of NO. The positive interaction observed between BAY 41-2272 and various NO donors is qualitatively similar whatever the mechanism involved in NO release. Furthermore, a potent synergism is observed between BAY 41-2272 and a prostacyclin analogue, but only in the presence of NO.
BACKGROUND AND PURPOSE: The purpose of the present study was to determine whether a stimulator of soluble guanylyl cyclase, BAY 41-2272, inhibits platelet aggregation and to clarify its interaction with nitric oxide (NO). EXPERIMENTAL APPROACH: Blood was collected from anaesthetized Wistar Kyoto rats. The aggregation of washed platelets was measured and the production of cAMP and cGMP was determined. KEY RESULTS: In adenosine 5'-diphosphate (ADP)-induced platelet aggregation, the anti-aggregating effects of BAY 41-2272, nitroglycerin, sodium nitroprusside and DEA-NONOate were associated with increased levels of cGMP while that of beraprost, a prostacyclin analogue, was correlated with an increase in cAMP. 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) prevented the effects of BAY 41-2272 and that of nitroglycerin and sodium nitroprusside, but only inhibited the increase in cGMP produced by of DEA-NONOate. Hydroxocobalamin, an NO scavenger, inhibited the effects of the three NO donors and BAY 41-2272 but did not affect those of beraprost. ADP-induced aggregation and the effects of BAY 41-2272 were not affected by L-nitroarginine. A positive interaction was observed between BAY 41-2272 and the three NO donors. BAY 41-2272 potentiated also the anti-aggregating effects of beraprost, and again this potentiation was inhibited by hydroxocobalamin. CONCLUSIONS AND IMPLICATIONS: Inhibition of platelet aggregation by BAY 41-2272 requires the reduced form of soluble guanylyl cyclase and the presence of NO. The positive interaction observed between BAY 41-2272 and various NO donors is qualitatively similar whatever the mechanism involved in NO release. Furthermore, a potent synergism is observed between BAY 41-2272 and a prostacyclin analogue, but only in the presence of NO.
Authors: Oleg V Evgenov; Pál Pacher; Peter M Schmidt; György Haskó; Harald H H W Schmidt; Johannes-Peter Stasch Journal: Nat Rev Drug Discov Date: 2006-09 Impact factor: 84.694
Authors: Johannes-Peter Stasch; Peter M Schmidt; Pavel I Nedvetsky; Tatiana Y Nedvetskaya; Arun Kumar H S; Sabine Meurer; Martin Deile; Ashraf Taye; Andreas Knorr; Harald Lapp; Helmut Müller; Yagmur Turgay; Christiane Rothkegel; Adrian Tersteegen; Barbara Kemp-Harper; Werner Müller-Esterl; Harald H H W Schmidt Journal: J Clin Invest Date: 2006-09 Impact factor: 14.808
Authors: S Gambaryan; A Kobsar; S Hartmann; I Birschmann; P J Kuhlencordt; W Müller-Esterl; S M Lohmann; U Walter Journal: J Thromb Haemost Date: 2008-05-14 Impact factor: 5.824
Authors: Jennifer C Irvine; Virat Ganthavee; Jane E Love; Amy E Alexander; John D Horowitz; Johannes-Peter Stasch; Barbara K Kemp-Harper; Rebecca H Ritchie Journal: PLoS One Date: 2012-11-07 Impact factor: 3.240
Authors: Camila B Mendes-Silverio; Luiz O S Leiria; Rafael P Morganti; Gabriel F Anhê; Sisi Marcondes; Fabíola Z Mónica; Gilberto De Nucci; Edson Antunes Journal: PLoS One Date: 2012-11-08 Impact factor: 3.240
Authors: Shaquria P Adderley; Chintamani N Joshi; Danielle N Martin; David Anthony Tulis Journal: Front Pharmacol Date: 2012-02-07 Impact factor: 5.810
Authors: Priscila F Monteiro; Rafael P Morganti; Maria A Delbin; Marina C Calixto; Maria E Lopes-Pires; Sisi Marcondes; Angelina Zanesco; Edson Antunes Journal: Cardiovasc Diabetol Date: 2012-01-16 Impact factor: 9.951